4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-22-063026
Chief Executive Officer sold 25,000 shares at an average $40.93 ($1,023,290)
- Chief Executive Officer acquired 25,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2022-12-28 | Option exercise | +25,000 | $19.12 | $478,000 | 394,111 | D: show line 1 in the form |
| Kulkarni Samarth Chief Executive Officer | 2022-12-28 | Sale | −20,366 | $40.81 | $831,189 | 373,745 | D: show line 2 in the form |
| Kulkarni Samarth Chief Executive Officer | 2022-12-28 | Sale | −4,634 | $41.45 | $192,101 | 369,111 | D: show line 3 in the form |
| Open-market sales · 25,000 sh · avg $40.93 · $1,023,290 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2022-12-28 | Option exercise · Stock Option (Right to Buy) | −25,000 | 204,582 | D: show line 4 in the form |
Loading xslF345X03/doc4.xml…